256 related articles for article (PubMed ID: 31312928)
1. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
3. Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications.
Mies A; Bulycheva E; Rogulj IM; Hofbauer LC; Platzbecker U
Curr Pharm Des; 2016; 22(16):2323-32. PubMed ID: 26916019
[TBL] [Abstract][Full Text] [Related]
4. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
7. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
9. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
10. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
11. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.
Balaian E; Wobus M; Weidner H; Baschant U; Stiehler M; Ehninger G; Bornhäuser M; Hofbauer LC; Rauner M; Platzbecker U
Haematologica; 2018 Jan; 103(1):61-68. PubMed ID: 29079596
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.
Medyouf H; Mossner M; Jann JC; Nolte F; Raffel S; Herrmann C; Lier A; Eisen C; Nowak V; Zens B; Müdder K; Klein C; Obländer J; Fey S; Vogler J; Fabarius A; Riedl E; Roehl H; Kohlmann A; Staller M; Haferlach C; Müller N; John T; Platzbecker U; Metzgeroth G; Hofmann WK; Trumpp A; Nowak D
Cell Stem Cell; 2014 Jun; 14(6):824-37. PubMed ID: 24704494
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
18. Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.
Flores-Figueroa E; Gratzinger D
Int J Mol Sci; 2016 Apr; 17(4):553. PubMed ID: 27089321
[TBL] [Abstract][Full Text] [Related]
19. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Garcia-Manero G; Fenaux P; Al-Kali A; Baer MR; Sekeres MA; Roboz GJ; Gaidano G; Scott BL; Greenberg P; Platzbecker U; Steensma DP; Kambhampati S; Kreuzer KA; Godley LA; Atallah E; Collins R; Kantarjian H; Jabbour E; Wilhelm FE; Azarnia N; Silverman LR;
Lancet Oncol; 2016 Apr; 17(4):496-508. PubMed ID: 26968357
[TBL] [Abstract][Full Text] [Related]
20. Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.
Roversi FM; Lopes MR; Machado-Neto JA; Longhini AL; Duarte Ada S; Baratti MO; Palodetto B; Corrocher FA; Pericole FV; Campos Pde M; Favaro P; Traina F; Saad ST
Stem Cells Dev; 2014 May; 23(10):1109-20. PubMed ID: 24410667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]